Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Supportive Care

Learn more about the nature of hyperuricemia and its various treatment options.
Corneal toxicity with high-dose cytarabine is a well-established risk of therapy. Routine prophylaxis with eye drops, usually topical corticosteroid drops, is an established part of high-dose cytarabine treatment protocols. Without topical corticosteroid prophylaxis, incidences of keratoconjunctivitis have been reported in 85% to 100% of cases; the occurrence of clinically significant symptoms with the use of prophylaxis is reported in 8% to 16% of cases.
Hiccups are an underreported respiratory complication that can significantly impair an individual’s quality of life.
The effects of CIPN are generally symmetrical, distal, in a stocking-glove distribution, and primarily affect the upper and lower extremities. These are usually sensory effects (burning, freezing, electroshock-like); however, there are more agent-specific neuropathies, such as constipation seen with vincristine; orthostasis with bortezomib; or temperature-related effects with oxaliplatin.
Diarrhea is a well-recognized side effect that is associated with various phases of a patient with cancer’s treatment cycle. Radiotherapy, chemotherapy, infection, and graft-versus-host disease can all potentially augment this dose-limiting toxicity. Some regimens, especially those targeting colorectal cancer (CRC) and other malignancies of the gastrointestinal (GI) tract, are associated with an increased incidence of severe or refractory chemotherapy-induced diarrhea (CID). In some studies, CID has been reported as a side effect in up to 82% of patients with cancer, with up to 33% experiencing grades 3 and 4 diarrhea.1 GI toxicity has also been linked to many cases of death and is often an underrecognized and undertreated complication of chemotherapy.2

SAN DIEGO—Current or recent tamoxifen therapy was associated with an increased risk of developing type 2 diabetes in women older than 65 years who survived invasive breast cancer. No association was found between aromatase inhibitors (AIs) and development of type 2 diabetes, but the numbers of women on AIs was small. These findings of a population-based, case-control study in Toronto, Ontario, Canada, were presented at the 71st Scientific Sessions of the American Diabetes Association.

This past Friday, the US Food and Drug Administration (FDA) approved 2 drugs that could help our patients: fentanyl nasal spray (Lazanda, Archimedes Pharma) and rivaroxaban (Xarelto, Janssen Pharmaceuticals).

 

Use of hormone therapy for menopause is associated with reduced risks for esophageal, gastric, and colorectal cancers, according to results of a prospective study that were then combined with published studies in a meta-analysis. In this British study of women aged 50 to 64 years, researchers found no significant differences in risk by type of hormone therapy, duration of use, or between past and current users. The reduction in risk, however, was small in comparison to the increased risk of breast cancer that has been attributed to hormone therapy in this population.

Up to 39% of cancer patient believed they did not receive the physical rehabilitation they needed, and 10% to 24% believed they did not receive other rehabilitation services they required. These are the findings of a group of Danish researchers who used the Oncology Nursing Society definition of “a process by which individuals within their environments are assisted to achieve optimal functioning within limits imposed by cancer,” to survey 2202 cancer patients regarding their perception of the rehabilitation they received.

Page 2 of 3
Results 11 - 20 of 28